Cargando…

A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications

Specific niches within the tumor bone marrow (BM) microenvironment afford a sanctuary for multiple myeloma (MM) clones due to stromal cell-tumor cell interactions, which confer survival advantage and drug resistance. Defining the sequelae of tumor cell interactions within the MM niches on an individ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jakubikova, Jana, Cholujova, Danka, Hideshima, Teru, Gronesova, Paulina, Soltysova, Andrea, Harada, Takeshi, Joo, Jungnam, Kong, Sun-Young, Szalat, Raphael E., Richardson, Paul G., Munshi, Nikhil C., Dorfman, David M., Anderson, Kenneth C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357212/ https://www.ncbi.nlm.nih.gov/pubmed/27764795 http://dx.doi.org/10.18632/oncotarget.12643

Ejemplares similares

Heterogeneity of B cell lymphopoiesis in patients with premalignant and active myeloma
por: Jakubikova, Jana, et al.
Publicado: (2023)

Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy
por: Richardson, Paul, et al.
Publicado: (2010)

In vitro and ex vivo anti-myeloma effects of nanocomposite As(4)S(4)/ZnS/Fe(3)O(4)
por: Cholujova, Danka, et al.
Publicado: (2022)

Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells
por: Suzuki, Rikio, et al.
Publicado: (2015)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

The Treatment of Multiple Myeloma Patients Not Eligible for Asct
por: Richardson, Paul, et al.
Publicado: (2010)

Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma
por: Hideshima, T, et al.
Publicado: (2015)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
por: van de Donk, Niels WCJ, et al.
Publicado: (2012)

Investigation of the Interaction between Mechanosynthesized ZnS Nanoparticles and Albumin Using Fluorescence Spectroscopy
por: Lukáčová Bujňáková, Zdenka, et al.
Publicado: (2023)

A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma
por: Hideshima, Teru, et al.
Publicado: (2008)

Signaling Pathway Mediating Myeloma Cell Growth and Survival
por: Hideshima, Teru, et al.
Publicado: (2021)

KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival
por: Ohguchi, Hiroto, et al.
Publicado: (2017)

PRMT5 inhibitors on the (myeloma) road
por: Gulla, Annamaria, et al.
Publicado: (2018)

Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma
por: Bae, Jooeun, et al.
Publicado: (2021)

The biological significance of histone modifiers in multiple myeloma: clinical applications
por: Ohguchi, Hiroto, et al.
Publicado: (2018)

Protein Arginine Methyltransferase 5 (PRMT5) has prognostic relevance and is a druggable target in Multiple Myeloma
por: Gullà, Annamaria, et al.
Publicado: (2017)

Author Correction: The biological significance of histone modifiers in multiple myeloma: clinical applications
por: Ohguchi, Hiroto, et al.
Publicado: (2021)

HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications
por: Harada, Takeshi, et al.
Publicado: (2017)

Antitumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma
por: Suzuki, Rikio, et al.
Publicado: (2014)

Decreased levels of circulating cytokines VEGF, TNF-β and IL-15 indicate PD-L1 overexpression in tumours of primary breast cancer patients
por: Cierna, Zuzana, et al.
Publicado: (2021)

Genetic Predictors of Mortality in Patients with Multiple Myeloma
por: Hassan, Hamza, et al.
Publicado: (2021)

SDS-Stabilized CuInSe(2)/ZnS Multinanocomposites Prepared by Mechanochemical Synthesis for Advanced Biomedical Application
por: Dutková, Erika, et al.
Publicado: (2020)

Bone marrow niche in multiple myeloma and its precursor states
por: Sklavenitis-Pistofidis, Romanos, et al.
Publicado: (2019)

ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment
por: Liu, Jiye, et al.
Publicado: (2021)

The KDM3A–KLF2–IRF4 axis maintains myeloma cell survival
por: Ohguchi, Hiroto, et al.
Publicado: (2016)

PB2155: TARGETING NEUROBIOLOGICAL MECHANISMS IN PATIENTS WITH MULTIPLE MYELOMA HAS IMPROVED THEIR PLASMACYTOID DENDRITIC CELLS CD123+, B LYMPHOCYTE MEMORY CELLS CD27+, VAGAL ACTIVITY AND DISTRESS.
por: Kotoucek, Pavel, et al.
Publicado: (2023)

Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma
por: Adamia, Sophia, et al.
Publicado: (2022)

Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group
por: Samur, Mehmet Kemal, et al.
Publicado: (2020)

Author Correction: Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma
por: Adamia, Sophia, et al.
Publicado: (2022)

Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche
por: Solimando, Antonio Giovanni, et al.
Publicado: (2022)

Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling
por: Ho, Matthew, et al.
Publicado: (2019)

Small Molecule Multi-Targeted Kinase Inhibitor RGB-286638 Triggers P53-Dependent and -Independent Anti-Multiple Myeloma Activity through Inhibition of Transcriptional CDKs
por: Cirstea, Diana, et al.
Publicado: (2013)

The Ins and Outs of Endosteal Niche Disruption in the Bone Marrow: Relevance for Myeloma Oncogenesis
por: Capp, Jean-Pascal, et al.
Publicado: (2023)

The Cyclophilin A-CD147 complex promotes bone marrow colonization of B-cell malignancies: implications for therapy
por: Zhu, Di, et al.
Publicado: (2015)

Long Intergenic Non-Coding RNAs have an Independent Impact on Survival in Multiple Myeloma
por: Samur, Mehmet Kemal, et al.
Publicado: (2018)

Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma
por: Fulciniti, Mariateresa, et al.
Publicado: (2018)

Retraction: Fatty acid synthase is a novel therapeutic target in multiple myeloma
por: Okawa, Yutaka, et al.
Publicado: (2008)

Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways
por: Hideshima, Teru, et al.
Publicado: (2020)

Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics
por: Ogiya, Daisuke, et al.
Publicado: (2023)

Cellular immunotherapy on primary multiple myeloma expanded in a 3D bone marrow niche model
por: Braham, Maaike V. J., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_nc96o6qec92bb2nq887plb835e